Skip to main content
Equibles

D. E. Shaw & Co., Inc.

Position in MLTX — MoonLake Immunotherapeutics

CIK 1009207 New York, NY
Back to MLTX Full portfolio

Position in MLTX

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$65,526,421
+$20,964,500 QoQ
Shares Held
3,365,507
+40.8% QoQ
Ownership
3.95%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#4
of 172 holders
Holding Since
Jun 2021
9 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in MLTX Over Time

Shares Held

Position Value (USD)

Derivatives in MLTX

reported options exposure · as of Sep 30, 2025
CallValue
$661,791
CallShares
92,300
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

D. E. Shaw & Co., Inc. holds $5,139,216,221 across 216 Biotechnology names. MLTX ranks #20 (1.3% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 INSM
INSMED Inc
 5,877,959 $626,707,987
2 ALNY
Alnylam Pharmaceuticals, Inc.
 1,104,109 $332,369,932
3 EXEL
Exelixis, Inc.
 5,551,747 $302,070,554
4 BBIO
BridgeBio Pharma, Inc.
 3,633,007 $270,586,360
5 TGTX
Tg Therapeutics, Inc.
 3,400,808 $186,840,390
6 HALO
Halozyme Therapeutics, Inc.
 2,006,479 $157,047,110
7 AXSM
Axsome Therapeutics, Inc.
 604,753 $148,025,391
8 PTCT
Ptc Therapeutics, Inc.
 1,548,919 $126,345,322

All Filings in MLTX

Export CSV
5 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $65,526,421 3,365,507
2026-03-31 $44,561,921 2,390,661
2025-12-31 $32,696,509 2,480,767
2025-09-30 $661,791 92,300
2023-12-31 $7,772,193 128,700